As pharmaceutical researchers develop new therapeutics targeting those symptoms that matter most to patients, they are faced with the challenge of how to measure these outcomes in clinical trials.

TORONTO (PRWEB)
November 16, 2020

Substantial progress has been made in the development of disease modifying therapeutics for Multiple Sclerosis (MS) in recent years. The array of next-generation compounds for this complicated disease have made great strides in increasing the time between relapse and delaying disease progression. Future treatment options must go beyond new routes of administration and dosing frequency to listen closely to the MS patient voice and address the additional—and often less visible—symptoms that impact health outcomes and quality of life.

Cognitive function and motor abilities have been noted by patients as being some of the most disabling aspects of the disease. Earlier, more precise identification of change or decline in motor abilities may shed light on aspects of therapeutic response or disease progression with relevance for patients and family members.

As pharmaceutical researchers develop new therapeutics targeting those symptoms that matter most to patients, they are faced with the challenge of how to measure these outcomes in clinical trials.

This webinar will present advances in validated tools and technologies to collect digital endpoints relevant to MS and other neuromuscular diseases that can improve signal detection and gather relevant data needed to measure treatment response. The speakers will review examples of how these technologies have provided high quality outcome measures via sensitive, reliable and objective assessments which fully characterize motor and cognitive impairment.

Join Fay Horak, PhD, Chief Scientist, Wearables & Digital Biomarkers, ERT; and Chris Edgar, PhD, Chief Science Officer, Cogstate in a live webinar on Tuesday, December 1, 2020 at 11am EST (4pm GMT/UK).

For more information, or to register for this event, visit Digital Technologies for Assessing Patient Functioning in Multiple Sclerosis Clinical Trials.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email: